Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer
Colorectal Cancer
About this trial
This is an interventional treatment trial for Colorectal Cancer focused on measuring stage IV colon cancer, stage IV rectal cancer, recurrent colon cancer, recurrent rectal cancer
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of metastatic carcinoma of the colon or rectum Recurrent or progressive after failing prior fluorouracil and irinotecan chemotherapy, sequentially or in combination, unless unable to tolerate irinotecan Measurable disease PATIENT CHARACTERISTICS: Age: 18 to 75 Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hemoglobin at least 10 g/dL Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) AST and ALT no greater than 5 times ULN PT/aPTT no greater than 1.2 times ULN Renal: Creatinine no greater than 1.5 mg/dL Creatinine clearance at least 50 mL/min No impaired renal function Cardiovascular: No impaired cardiac function Other: No active infection No other malignancy within the past 5 years except basal cell or squamous cell skin cancer Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 4 weeks since prior chemotherapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks since prior radiotherapy Surgery: Not specified Other: No other concurrent anticancer drugs No concurrent chronic non-steroidal anti-inflammatory agents No concurrent chronic therapeutic anticoagulation
Sites / Locations
- Jonsson Comprehensive Cancer Center, UCLA